Incidence and prevalence of NMOSD in Australia and New Zealand

Wajih Bukhari, Kerri M. Prain, Patrick Waters, Mark Woodhall, Cullen M. O'Gorman, Laura Clarke, Roger A. Silvestrini, Christine S. Bundell, David Abernethy, Sandeep Bhuta, Stefan Blum, Mike Boggild, Karyn Boundy, Bruce J. Brew, Matthew Brown, Wallace J. Brownlee, Helmut Butzkueven, William M. Carroll, Celia Chen, Alan Coulthard & 43 others Russell C. Dale, Chandi Das, Keith Dear, Marzena J. Fabis-Pedrini, David Fulcher, David Gillis, Simon Hawke, Robert Heard, Andrew P.D. Henderson, Saman Heshmat, Suzanne Hodgkinson, Sofia Jimenez-Sanchez, Trevor Killpatrick, John King, Christopher Kneebone, Andrew J. Kornberg, Jeannette Lechner-Scott, Ming Wei Lin, Christpher Lynch, Richard Macdonell, Deborah F. Mason, Pamela A. McCombe, Michael P. Pender, Jennifer A. Pereira, John D. Pollard, Stephen W. Reddel, Cameron Shaw, Judith Spies, James Stankovich, Ian Sutton, Steve Vucic, Richard C. Wong, Eppie M. Yiu, Michael H. Barnett, Allan G. Kermode, Mark P. Marriott, John D.E. Parratt, Mark Slee, Bruce V. Taylor, Ernest Willoughby, Robert J. Wilson, Angela Vincent, Simon A. Broadley

Research output: Contribution to journalArticle

21 Citations (Scopus)
215 Downloads (Pure)

Abstract

Objectives: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry. Background: NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established. Methods: Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for aquaporin 4 antibodies was undertaken in all suspected cases. From this group, cases were identified who fulfilled the 2015 Wingerchuk diagnostic criteria for NMOSD. A capture-recapture methodology was used to estimate incidence and prevalence, based on additional laboratory identified cases. Results: NMOSD was confirmed in 81/170 (48%) cases referred. Capture-recapture analysis gave an adjusted incidence estimate of 0.37 (95% CI 0.35 to 0.39) per million per year and a prevalence estimate for NMOSD of 0.70 (95% CI 0.61 to 0.78) per 100 000. NMOSD was three times more common in the Asian population (1.57 (95% CI 1.15 to 1.98) per 100 000) compared with the remainder of the population (0.57 (95% CI 0.50 to 0.65) per 100 000). The latitudinal gradient evident in multiple sclerosis was not seen in NMOSD. Conclusions: NMOSD incidence and prevalence in Australia and New Zealand are comparable with figures from other populations of largely European ancestry. We found NMOSD to be more common in the population with Asian ancestry.

Original languageEnglish
Pages (from-to)632-638
Number of pages7
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume88
Issue number8
DOIs
Publication statusPublished - 1 Aug 2017

Fingerprint

Neuromyelitis Optica
New Zealand
Incidence
Population
Demyelinating Diseases
Central Nervous System
Aquaporin 4
Multiple Sclerosis

Cite this

Bukhari, W., Prain, K. M., Waters, P., Woodhall, M., O'Gorman, C. M., Clarke, L., ... Broadley, S. A. (2017). Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry, 88(8), 632-638. https://doi.org/10.1136/jnnp-2016-314839
Bukhari, Wajih ; Prain, Kerri M. ; Waters, Patrick ; Woodhall, Mark ; O'Gorman, Cullen M. ; Clarke, Laura ; Silvestrini, Roger A. ; Bundell, Christine S. ; Abernethy, David ; Bhuta, Sandeep ; Blum, Stefan ; Boggild, Mike ; Boundy, Karyn ; Brew, Bruce J. ; Brown, Matthew ; Brownlee, Wallace J. ; Butzkueven, Helmut ; Carroll, William M. ; Chen, Celia ; Coulthard, Alan ; Dale, Russell C. ; Das, Chandi ; Dear, Keith ; Fabis-Pedrini, Marzena J. ; Fulcher, David ; Gillis, David ; Hawke, Simon ; Heard, Robert ; Henderson, Andrew P.D. ; Heshmat, Saman ; Hodgkinson, Suzanne ; Jimenez-Sanchez, Sofia ; Killpatrick, Trevor ; King, John ; Kneebone, Christopher ; Kornberg, Andrew J. ; Lechner-Scott, Jeannette ; Lin, Ming Wei ; Lynch, Christpher ; Macdonell, Richard ; Mason, Deborah F. ; McCombe, Pamela A. ; Pender, Michael P. ; Pereira, Jennifer A. ; Pollard, John D. ; Reddel, Stephen W. ; Shaw, Cameron ; Spies, Judith ; Stankovich, James ; Sutton, Ian ; Vucic, Steve ; Wong, Richard C. ; Yiu, Eppie M. ; Barnett, Michael H. ; Kermode, Allan G. ; Marriott, Mark P. ; Parratt, John D.E. ; Slee, Mark ; Taylor, Bruce V. ; Willoughby, Ernest ; Wilson, Robert J. ; Vincent, Angela ; Broadley, Simon A. / Incidence and prevalence of NMOSD in Australia and New Zealand. In: Journal of Neurology, Neurosurgery and Psychiatry. 2017 ; Vol. 88, No. 8. pp. 632-638.
@article{5926f531ae544c43a10e13b871516154,
title = "Incidence and prevalence of NMOSD in Australia and New Zealand",
abstract = "Objectives: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry. Background: NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established. Methods: Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for aquaporin 4 antibodies was undertaken in all suspected cases. From this group, cases were identified who fulfilled the 2015 Wingerchuk diagnostic criteria for NMOSD. A capture-recapture methodology was used to estimate incidence and prevalence, based on additional laboratory identified cases. Results: NMOSD was confirmed in 81/170 (48{\%}) cases referred. Capture-recapture analysis gave an adjusted incidence estimate of 0.37 (95{\%} CI 0.35 to 0.39) per million per year and a prevalence estimate for NMOSD of 0.70 (95{\%} CI 0.61 to 0.78) per 100 000. NMOSD was three times more common in the Asian population (1.57 (95{\%} CI 1.15 to 1.98) per 100 000) compared with the remainder of the population (0.57 (95{\%} CI 0.50 to 0.65) per 100 000). The latitudinal gradient evident in multiple sclerosis was not seen in NMOSD. Conclusions: NMOSD incidence and prevalence in Australia and New Zealand are comparable with figures from other populations of largely European ancestry. We found NMOSD to be more common in the population with Asian ancestry.",
keywords = "Ancestry, Epidemiology, Incidence, Neuroimmunology, Prevalence",
author = "Wajih Bukhari and Prain, {Kerri M.} and Patrick Waters and Mark Woodhall and O'Gorman, {Cullen M.} and Laura Clarke and Silvestrini, {Roger A.} and Bundell, {Christine S.} and David Abernethy and Sandeep Bhuta and Stefan Blum and Mike Boggild and Karyn Boundy and Brew, {Bruce J.} and Matthew Brown and Brownlee, {Wallace J.} and Helmut Butzkueven and Carroll, {William M.} and Celia Chen and Alan Coulthard and Dale, {Russell C.} and Chandi Das and Keith Dear and Fabis-Pedrini, {Marzena J.} and David Fulcher and David Gillis and Simon Hawke and Robert Heard and Henderson, {Andrew P.D.} and Saman Heshmat and Suzanne Hodgkinson and Sofia Jimenez-Sanchez and Trevor Killpatrick and John King and Christopher Kneebone and Kornberg, {Andrew J.} and Jeannette Lechner-Scott and Lin, {Ming Wei} and Christpher Lynch and Richard Macdonell and Mason, {Deborah F.} and McCombe, {Pamela A.} and Pender, {Michael P.} and Pereira, {Jennifer A.} and Pollard, {John D.} and Reddel, {Stephen W.} and Cameron Shaw and Judith Spies and James Stankovich and Ian Sutton and Steve Vucic and Wong, {Richard C.} and Yiu, {Eppie M.} and Barnett, {Michael H.} and Kermode, {Allan G.} and Marriott, {Mark P.} and Parratt, {John D.E.} and Mark Slee and Taylor, {Bruce V.} and Ernest Willoughby and Wilson, {Robert J.} and Angela Vincent and Broadley, {Simon A.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1136/jnnp-2016-314839",
language = "English",
volume = "88",
pages = "632--638",
journal = "Journal of Neurology and Neurosurgical Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "8",

}

Bukhari, W, Prain, KM, Waters, P, Woodhall, M, O'Gorman, CM, Clarke, L, Silvestrini, RA, Bundell, CS, Abernethy, D, Bhuta, S, Blum, S, Boggild, M, Boundy, K, Brew, BJ, Brown, M, Brownlee, WJ, Butzkueven, H, Carroll, WM, Chen, C, Coulthard, A, Dale, RC, Das, C, Dear, K, Fabis-Pedrini, MJ, Fulcher, D, Gillis, D, Hawke, S, Heard, R, Henderson, APD, Heshmat, S, Hodgkinson, S, Jimenez-Sanchez, S, Killpatrick, T, King, J, Kneebone, C, Kornberg, AJ, Lechner-Scott, J, Lin, MW, Lynch, C, Macdonell, R, Mason, DF, McCombe, PA, Pender, MP, Pereira, JA, Pollard, JD, Reddel, SW, Shaw, C, Spies, J, Stankovich, J, Sutton, I, Vucic, S, Wong, RC, Yiu, EM, Barnett, MH, Kermode, AG, Marriott, MP, Parratt, JDE, Slee, M, Taylor, BV, Willoughby, E, Wilson, RJ, Vincent, A & Broadley, SA 2017, 'Incidence and prevalence of NMOSD in Australia and New Zealand' Journal of Neurology, Neurosurgery and Psychiatry, vol. 88, no. 8, pp. 632-638. https://doi.org/10.1136/jnnp-2016-314839

Incidence and prevalence of NMOSD in Australia and New Zealand. / Bukhari, Wajih; Prain, Kerri M.; Waters, Patrick; Woodhall, Mark; O'Gorman, Cullen M.; Clarke, Laura; Silvestrini, Roger A.; Bundell, Christine S.; Abernethy, David; Bhuta, Sandeep; Blum, Stefan; Boggild, Mike; Boundy, Karyn; Brew, Bruce J.; Brown, Matthew; Brownlee, Wallace J.; Butzkueven, Helmut; Carroll, William M.; Chen, Celia; Coulthard, Alan; Dale, Russell C.; Das, Chandi; Dear, Keith; Fabis-Pedrini, Marzena J.; Fulcher, David; Gillis, David; Hawke, Simon; Heard, Robert; Henderson, Andrew P.D.; Heshmat, Saman; Hodgkinson, Suzanne; Jimenez-Sanchez, Sofia; Killpatrick, Trevor; King, John; Kneebone, Christopher; Kornberg, Andrew J.; Lechner-Scott, Jeannette; Lin, Ming Wei; Lynch, Christpher; Macdonell, Richard; Mason, Deborah F.; McCombe, Pamela A.; Pender, Michael P.; Pereira, Jennifer A.; Pollard, John D.; Reddel, Stephen W.; Shaw, Cameron; Spies, Judith; Stankovich, James; Sutton, Ian; Vucic, Steve; Wong, Richard C.; Yiu, Eppie M.; Barnett, Michael H.; Kermode, Allan G.; Marriott, Mark P.; Parratt, John D.E.; Slee, Mark; Taylor, Bruce V.; Willoughby, Ernest; Wilson, Robert J.; Vincent, Angela; Broadley, Simon A.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 88, No. 8, 01.08.2017, p. 632-638.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Incidence and prevalence of NMOSD in Australia and New Zealand

AU - Bukhari, Wajih

AU - Prain, Kerri M.

AU - Waters, Patrick

AU - Woodhall, Mark

AU - O'Gorman, Cullen M.

AU - Clarke, Laura

AU - Silvestrini, Roger A.

AU - Bundell, Christine S.

AU - Abernethy, David

AU - Bhuta, Sandeep

AU - Blum, Stefan

AU - Boggild, Mike

AU - Boundy, Karyn

AU - Brew, Bruce J.

AU - Brown, Matthew

AU - Brownlee, Wallace J.

AU - Butzkueven, Helmut

AU - Carroll, William M.

AU - Chen, Celia

AU - Coulthard, Alan

AU - Dale, Russell C.

AU - Das, Chandi

AU - Dear, Keith

AU - Fabis-Pedrini, Marzena J.

AU - Fulcher, David

AU - Gillis, David

AU - Hawke, Simon

AU - Heard, Robert

AU - Henderson, Andrew P.D.

AU - Heshmat, Saman

AU - Hodgkinson, Suzanne

AU - Jimenez-Sanchez, Sofia

AU - Killpatrick, Trevor

AU - King, John

AU - Kneebone, Christopher

AU - Kornberg, Andrew J.

AU - Lechner-Scott, Jeannette

AU - Lin, Ming Wei

AU - Lynch, Christpher

AU - Macdonell, Richard

AU - Mason, Deborah F.

AU - McCombe, Pamela A.

AU - Pender, Michael P.

AU - Pereira, Jennifer A.

AU - Pollard, John D.

AU - Reddel, Stephen W.

AU - Shaw, Cameron

AU - Spies, Judith

AU - Stankovich, James

AU - Sutton, Ian

AU - Vucic, Steve

AU - Wong, Richard C.

AU - Yiu, Eppie M.

AU - Barnett, Michael H.

AU - Kermode, Allan G.

AU - Marriott, Mark P.

AU - Parratt, John D.E.

AU - Slee, Mark

AU - Taylor, Bruce V.

AU - Willoughby, Ernest

AU - Wilson, Robert J.

AU - Vincent, Angela

AU - Broadley, Simon A.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Objectives: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry. Background: NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established. Methods: Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for aquaporin 4 antibodies was undertaken in all suspected cases. From this group, cases were identified who fulfilled the 2015 Wingerchuk diagnostic criteria for NMOSD. A capture-recapture methodology was used to estimate incidence and prevalence, based on additional laboratory identified cases. Results: NMOSD was confirmed in 81/170 (48%) cases referred. Capture-recapture analysis gave an adjusted incidence estimate of 0.37 (95% CI 0.35 to 0.39) per million per year and a prevalence estimate for NMOSD of 0.70 (95% CI 0.61 to 0.78) per 100 000. NMOSD was three times more common in the Asian population (1.57 (95% CI 1.15 to 1.98) per 100 000) compared with the remainder of the population (0.57 (95% CI 0.50 to 0.65) per 100 000). The latitudinal gradient evident in multiple sclerosis was not seen in NMOSD. Conclusions: NMOSD incidence and prevalence in Australia and New Zealand are comparable with figures from other populations of largely European ancestry. We found NMOSD to be more common in the population with Asian ancestry.

AB - Objectives: We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry. Background: NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established. Methods: Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for aquaporin 4 antibodies was undertaken in all suspected cases. From this group, cases were identified who fulfilled the 2015 Wingerchuk diagnostic criteria for NMOSD. A capture-recapture methodology was used to estimate incidence and prevalence, based on additional laboratory identified cases. Results: NMOSD was confirmed in 81/170 (48%) cases referred. Capture-recapture analysis gave an adjusted incidence estimate of 0.37 (95% CI 0.35 to 0.39) per million per year and a prevalence estimate for NMOSD of 0.70 (95% CI 0.61 to 0.78) per 100 000. NMOSD was three times more common in the Asian population (1.57 (95% CI 1.15 to 1.98) per 100 000) compared with the remainder of the population (0.57 (95% CI 0.50 to 0.65) per 100 000). The latitudinal gradient evident in multiple sclerosis was not seen in NMOSD. Conclusions: NMOSD incidence and prevalence in Australia and New Zealand are comparable with figures from other populations of largely European ancestry. We found NMOSD to be more common in the population with Asian ancestry.

KW - Ancestry

KW - Epidemiology

KW - Incidence

KW - Neuroimmunology

KW - Prevalence

UR - http://www.scopus.com/inward/record.url?scp=85024392871&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2016-314839

DO - 10.1136/jnnp-2016-314839

M3 - Article

VL - 88

SP - 632

EP - 638

JO - Journal of Neurology and Neurosurgical Psychiatry

JF - Journal of Neurology and Neurosurgical Psychiatry

SN - 0022-3050

IS - 8

ER -

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L et al. Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry. 2017 Aug 1;88(8):632-638. https://doi.org/10.1136/jnnp-2016-314839